RT Journal Article SR Electronic T1 Comparison of effectiveness and safety of imipenem/clavulanate-versusmeropenem / t clavulanate-containing方案reatment of MDR- and XDR-TB JF European Respiratory Journal JO Eur Respir J FD European Respiratory Society SP 1758 OP 1766 DO 10.1183/13993003.00214-2016 VO 47 IS 6 A1 Tiberi, Simon A1 Sotgiu, Giovanni A1 D'Ambrosio, Lia A1 Centis, Rosella A1 Abdo Arbex, Marcos A1 Alarcon Arrascue, Edith A1 Alffenaar, Jan Willem A1 Caminero, Jose A. A1 Gaga, Mina A1 Gualano, Gina A1 Skrahina, Alena A1 Solovic, Ivan A1 Sulis, Giorgia A1 Tadolini, Marina A1 Alarcon Guizado, Valentina A1 De Lorenzo, Saverio A1 Roby Arias, Aurora Jazmín A1 Scardigli, Anna A1 Akkerman, Onno W. A1 Aleksa, Alena A1 Artsukevich, Janina A1 Auchynka, Vera A1 Bonini, Eduardo Henrique A1 Chong Marín, Félix Antonio A1 Collahuazo López, Lorena A1 de Vries, Gerard A1 Dore, Simone A1 Kunst, Heinke A1 Matteelli, Alberto A1 Moschos, Charalampos A1 Palmieri, Fabrizio A1 Papavasileiou, Apostolos A1 Payen, Marie-Christine A1 Piana, Andrea A1 Spanevello, Antonio A1 Vargas Vasquez, Dante A1 Viggiani, Pietro A1 White, Veronica A1 Zumla, Alimuddin A1 Migliori, Giovanni Battista YR 2016 UL //www.qdcxjkg.com/content/47/6/1758.abstract AB No large study to date has ever evaluated the effectiveness, safety and tolerability of imipenem/clavulanate versus meropenem/clavulanate to treat multidrug- and extensively drug-resistant tuberculosis (MDR- and XDR-TB). The aim of this observational study was to compare the therapeutic contribution of imipenem/clavulanate versus meropenem/clavulanate added to background regimens to treat MDR- and XDR-TB cases.84 patients treated with imipenem/clavulanate-containing regimens showed a similar median number of antibiotic resistances (8 versus 8) but more fluoroquinolone resistance (79.0% versus 48.9%, p<0.0001) and higher XDR-TB prevalence (67.9% versus 49.0%, p=0.01) in comparison with 96 patients exposed to meropenem/clavulanate-containing regimens. Patients were treated with imipenem/clavulanate- and meropenem/clavulanate-containing regimens for a median (interquartile range) of 187 (60–428) versus 85 (49–156) days, respectively.Statistically significant differences were observed on sputum smear and culture conversion rates (79.7% versus 94.8%, p=0.02 and 71.9% versus 94.8%, p<0.0001, respectively) and on success rates (59.7% versus 77.5%, p=0.03). Adverse events to imipenem/clavulanate and meropenem/clavulanate were reported in 5.4% and 6.5% of cases only.Our study suggests that meropenem/clavulanate is more effective than imipenem/clavulanate in treating MDR/XDR-TB patients.Meropenem/clavulanate is safe and more effective than imipenem/clavulanate in treating MDR and XDR-TB patients http://ow.ly/Z4S2o